Similar articles

• Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.

  Yu ML, Dai CY, Huang JF, Chuang WL. Yu ML, et al. Hepatology. 2008 Sep;48(3):1019-20; author reply 1020-1. doi: 10.1002/hep.22434. Hepatology. 2008. PMID: 18756469 No abstract available.
• Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

  Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Akuta N, et al. J Hepatol. 2007 Mar;46(3):403-10. doi: 10.1016/j.jhep.2006.09.019. Epub 2006 Nov 7. J Hepatol. 2007. PMID: 17126448 Clinical Trial.
• Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

  Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V. Martin-Carbonero L, et al. AIDS. 2008 Jan 2;22(1):15-21. doi: 10.1097/QAD.0b013e3282f1da99. AIDS. 2008. PMID: 18090387
• Peginterferon and ribavirin for chronic hepatitis C.

  Hoofnagle JH, Seeff LB. Hoofnagle JH, et al. N Engl J Med. 2006 Dec 7;355(23):2444-51. doi: 10.1056/NEJMct061675. N Engl J Med. 2006. PMID: 17151366 Review. No abstract available.
• Optimal therapy in genotype 1 patients.

  Farnik H, Mihm U, Zeuzem S. Farnik H, et al. Liver Int. 2009 Jan;29 Suppl 1:23-30. doi: 10.1111/j.1478-3231.2008.01969.x. Liver Int. 2009. PMID: 19207963 Review.